| 2026-09-03 | Press release | Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) |
| 2026-09-03 | Press release | LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China |
| 2026-09-01 | Press release | Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) |
| 2026-08-31 | Press release | Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease |
| 2026-08-27 | Press release | Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference |
| 2026-08-25 | Press release | Biogen to Participate in the Wells Fargo 21st Annual Healthcare Conference |
| 2026-08-24 | Press release | LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease |
| 2026-08-06 | Press release | Biogen Completes Acquisition of RayThera Inc |
| 2026-07-29 | Press release | Read more about Biogen to Report Second Quarter 2026 Financial Results |
| 2026-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-29 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-21 | Deck | Topline Results from CELIA: A Phase 2 Study to Evaluate the Tau-Targeting ASO Diranersen (BIIB080) in Patients with Earl |
| 2026-07-15 | Press release | Biogen Appoints Michael J. Parini as Chief Legal Officer |
| 2026-07-14 | Press release | LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the St |
| 2026-07-14 | Press release | Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Dira |
| 2026-07-14 | Press release | Read more about Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) |
| 2026-07-13 | Press release | FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease |
| 2026-07-12 | Press release | LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheim |
| 2026-07-01 | 8-K | Form 8-K, Item 2.02 results |
| 2026-06-29 | Press release | Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen |
| 2026-06-17 | Press release | Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc |
| 2026-06-10 | 8-K | Form 8-K/A, Item 9.01 |
| 2026-06-10 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-14 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-29 | Press release | Biogen reports strong first quarter 2026 results |
| 2026-04-29 | Deck | Q1 2026 Biogen Earnings Presentation |
| 2026-04-29 | Press release | Biogen to Report First Quarter 2026 Financial Results |
| 2026-04-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-29 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | Transcript | Q1 FY26 earnings call transcript |
| 2026-04-28 | Proxy | Definitive proxy statement |
| 2026-04-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-31 | Press release | Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology | Biogen |
| 2026-03-31 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-08 | Press release | Press release · Feb 2026 |
| 2026-02-06 | Deck | Q4 and Full Year 2025 Biogen Earnings Presentation |
| 2026-02-06 | Press release | Biogen Reports Fourth Quarter and Full Year 2025 Results |